Summit Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Operating Revenue	-	-	-	0.71	1.81	0.86	Upgrade
Revenue	-	-	-	0.71	1.81	0.86	Upgrade
Revenue Growth (YoY)	-	-	-	-61.03%	110.35%	6.10%	Upgrade
Gross Profit	-	-	-	0.71	1.81	0.86	Upgrade
Selling, General & Admin	411.2	60.53	30.27	26.74	23.61	19.23	Upgrade
Research & Development	348.39	150.78	59.47	52	85.35	53.27	Upgrade
Other Operating Expenses	-0.31	-0.31	-1	-14.42	-20.97	-19.31	Upgrade
Operating Expenses	759.28	210.99	88.74	64.33	88	53.19	Upgrade
Operating Income	-759.28	-210.99	-88.74	-63.62	-86.19	-52.33	Upgrade
Interest Expense	-2.46	-8.69	-16.46	-4.4	-0.24	-0.26	Upgrade
Interest & Investment Income	15.9	13.47	10.4	1.51	-	0	Upgrade
Currency Exchange Gain (Loss)	-0.18	-0.1	1.03	-4.11	-2.14	0.05	Upgrade
Other Non Operating Income (Expenses)	-0.05	-	-0.25	0.3	-0.04	0.48	Upgrade
EBT Excluding Unusual Items	-746.08	-206.31	-94.01	-70.31	-88.6	-52.05	Upgrade
Asset Writedown	-	-	-	-8.47	-	-0.86	Upgrade
Pretax Income	-746.08	-221.32	-614.93	-78.78	-88.6	-52.91	Upgrade
Income Tax Expense	-	-	-	-	-	-0.21	Upgrade
Net Income	-746.08	-221.32	-614.93	-78.78	-88.6	-52.7	Upgrade
Net Income to Common	-746.08	-221.32	-614.93	-78.78	-88.6	-52.7	Upgrade
Shares Outstanding (Basic)	736	719	620	193	92	70	Upgrade
Shares Outstanding (Diluted)	736	719	620	193	92	70	Upgrade
Shares Change (YoY)	4.79%	15.96%	220.50%	109.60%	32.67%	111.78%	Upgrade
EPS (Basic)	-1.01	-0.31	-0.99	-0.41	-0.96	-0.76	Upgrade
EPS (Diluted)	-1.01	-0.31	-0.99	-0.41	-0.96	-0.76	Upgrade
Free Cash Flow	-207.38	-142.25	-76.89	-42.21	-72.89	-48.53	Upgrade
Free Cash Flow Per Share	-0.28	-0.20	-0.12	-0.22	-0.79	-0.70	Upgrade
Gross Margin	-	-	-	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-	-	-	-9024.25%	-4764.29%	-6085.35%	Upgrade
Profit Margin	-	-	-	-11174.75%	-4897.84%	-6127.56%	Upgrade
Free Cash Flow Margin	-	-	-	-5986.67%	-4029.46%	-5643.26%	Upgrade
EBITDA	-759.18	-210.9	-88.54	-62.36	-84.84	-50.78	Upgrade
D&A For EBITDA	0.1	0.09	0.2	1.26	1.35	1.55	Upgrade
EBIT	-759.28	-210.99	-88.74	-63.62	-86.19	-52.33	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q